Osteoarthritis Injectables - Global Strategic Business Report

The global market for Osteoarthritis Injectables was estimated at US$7.5 Billion in 2024 and is projected to reach US$10.0 Billion by 2030, growing at a CAGR of 5.0% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The report includes the most recent global tariff developments and how they impact the Osteoarthritis Injectables market.

Global Osteoarthritis Injectables Market - Key Trends & Drivers Summarized

How Are Osteoarthritis Injectables Transforming Pain Management and Joint Care?

The osteoarthritis injectables market has gained significant traction as non-surgical treatment options for managing joint pain and inflammation become increasingly preferred. With osteoarthritis (OA) affecting millions worldwide, patients and healthcare providers are seeking minimally invasive solutions to delay or avoid joint replacement surgery. Injectable therapies, including corticosteroids, hyaluronic acid, platelet-rich plasma (PRP), and stem cell-based treatments, are being widely adopted due to their ability to provide targeted pain relief, improve joint mobility, and enhance cartilage health. The aging global population and rising obesity rates - two major risk factors for OA - are further fueling the demand for effective injectables that offer prolonged relief without the side effects associated with oral pain medications.

What Role Do Emerging Biologic and Regenerative Therapies Play in Osteoarthritis Treatment?

The landscape of osteoarthritis treatment is shifting with the increasing adoption of biologic injectables and regenerative medicine approaches. PRP therapy, which utilizes the patient`s own blood-derived growth factors, has gained popularity as a promising alternative to traditional steroid injections. Stem cell-based therapies are also emerging, offering the potential for cartilage regeneration and long-term disease modification rather than just symptomatic relief. Additionally, advancements in hyaluronic acid formulations, including cross-linked and combination therapies, are improving the durability and efficacy of viscosupplementation. Research into gene therapy and monoclonal antibodies targeting inflammatory pathways is also underway, promising next-generation injectable treatments that could revolutionize OA management.

What Are the Key Challenges Limiting the Adoption of Osteoarthritis Injectables?

Despite their effectiveness, several barriers exist in the widespread adoption of osteoarthritis injectables. High treatment costs, particularly for biologic and stem cell-based therapies, remain a significant concern, limiting accessibility for many patients. Additionally, variability in clinical outcomes and the lack of standardized protocols for emerging regenerative treatments pose challenges for regulatory approval and physician adoption. Some injectable therapies, such as corticosteroids, have been associated with potential side effects, including cartilage degradation with prolonged use, leading to cautious prescribing practices. However, ongoing research and clinical trials are working to address these limitations, refining formulations and optimizing dosing regimens to enhance treatment efficacy and safety.

What’s Fueling the Growth of the Osteoarthritis Injectables Market?

The growth in the osteoarthritis injectables market is driven by several factors, including the increasing prevalence of osteoarthritis, rising demand for minimally invasive treatments, and advancements in biologic and regenerative therapies. The growing preference for outpatient and in-office procedures has boosted the adoption of injectable therapies over surgical interventions. Additionally, the expansion of reimbursement policies covering hyaluronic acid and PRP injections in various countries is supporting market growth. The rising geriatric population, along with increasing investments in R&D for novel osteoarthritis therapeutics, is further accelerating market expansion. The emergence of next-generation

Report Scope

The report analyzes the Osteoarthritis Injectables market, presented in terms of market value (US$ Thousand). The analysis covers the key segments and geographic regions outlined below.

Segments: Injection (Hyaluronic Acid Injections, Corticosteroid Injections, Platelet-Rich Plasma Injections, Placental Tissue Matrix Injections, Acetylsalicylic Acid Injections, Other Injections); Anatomy (Knee Osteoarthritis, Hip Osteoarthritis, Hand Osteoarthritis, Other Anatomies); End-Use (Hospital Pharmacies End-Use, Retail Pharmacies End-Use, Other End-Uses)

Geographic Regions/Countries: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Key Insights:

• Market Growth: Understand the significant growth trajectory of the Hyaluronic Acid Injections segment, which is expected to reach US$2.5 Billion by 2030 with a CAGR of a 4.1%. The Corticosteroid Injections segment is also set to grow at 4.0% CAGR over the analysis period.
• Regional Analysis: Gain insights into the U.S. market, estimated at $2.0 Billion in 2024, and China, forecasted to grow at an impressive 7.8% CAGR to reach $2.0 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

• Detailed Market Analysis: Access a thorough analysis of the Global Osteoarthritis Injectables Market, covering all major geographic regions and market segments.
• Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
• Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Osteoarthritis Injectables Market.
• Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

• How is the Global Osteoarthritis Injectables Market expected to evolve by 2030?
• What are the main drivers and restraints affecting the market?
• Which market segments will grow the most over the forecast period?
• How will market shares for different regions and segments change by 2030?
• Who are the leading players in the market, and what are their prospects?

Report Features:

• Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030.
• In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
• Company Profiles: Coverage of players such as AbbVie Inc., Amgen Inc., Anika Therapeutics, Inc., Arthrex, Inc., Bayer AG and more.
• Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Select Competitors (Total 34 Featured):

• AbbVie Inc.
• Amgen Inc.
• Anika Therapeutics, Inc.
• Arthrex, Inc.
• Bayer AG
• Bioventus LLC
• Boehringer Ingelheim International GmbH
• Ferring Pharmaceuticals Inc.
• Fidia Farmaceutici S.p.A.
• Flexion Therapeutics, Inc.
• GlaxoSmithKline plc
• Merck & Co., Inc.
• Novartis AG
• Pfizer Inc.
• Samsung Bioepis Co., Ltd.
• Sanofi S.A.
• Seikagaku Corporation
• Sun Pharmaceutical Industries Ltd.
• Teva Pharmaceutical Industries Ltd.
• Zimmer Biomet Holdings, Inc.

Tariff Impact Analysis: Key Insights for 2025

Global tariff negotiations across 180+ countries are reshaping supply chains, costs, and competitiveness. This report reflects the latest developments as of April 2025 and incorporates forward-looking insights into the market outlook.

The analysts continuously track trade developments worldwide, drawing insights from leading global economists and over 200 industry and policy institutions, including think tanks, trade organizations, and national economic advisory bodies. This intelligence is integrated into forecasting models to provide timely, data-driven analysis of emerging risks and opportunities.

What’s Included in This Edition:

• Tariff-adjusted market forecasts by region and segment
• Analysis of cost and supply chain implications by sourcing and trade exposure
• Strategic insights into geographic shifts

Buyers receive a free July 2025 update with:

• Finalized tariff impacts and new trade agreement effects
• Updated projections reflecting global sourcing and cost shifts
• Expanded country-specific coverage across the industry